Publications by authors named "Daniel Jorissen"
Dysfunction of the epidermal growth factor receptor (EGFR) family, is the key process in tumorigenesis, and anti-EGFR therapeutic strategies such as cetuximab therapy now are used in the treatment of cancer. However, resistance to cetuximab is commonly reported. Comprehensive blockade of EGFR signaling using different antibodies might be critical to treat cancer effectively and limit drug resistance with potent novel mechanisms.
View Article and Find Full Text PDFArticle Synopsis
- Multiple anti-HER receptor antibodies like cetuximab, trastuzumab, and pertuzumab are common treatments for metastatic cancer, but drug resistance often arises due to HER-MET crosstalk.
- The study developed two new tetra-specific antibodies, FL518 and CRTB6, that target EGFR, HER2, HER3, and VEGF, effectively disrupting HER-MET interactions.
- These new tetra-specific antibodies demonstrated superior efficacy against anti-HER-resistant cancer cells compared to traditional bispecific antibodies, suggesting a novel approach to overcoming drug resistance.